Alector, Inc.

NasdaqGS:ALEC Voorraadrapport

Marktkapitalisatie: US$488.6m

Alector Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Alector's earnings have been declining at an average annual rate of -1.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 24.6% per year.

Belangrijke informatie

-1.2%

Groei van de winst

9.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei24.6%
Rendement op eigen vermogen-106.7%
Nettomarge-290.7%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

Oct 24
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Sep 26
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11
Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02
Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18
Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27
These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

Opbrengsten en kosten

Hoe Alector geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:ALEC Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2455-16157-6
31 Mar 2496-121560
31 Dec 2397-130570
30 Sep 2396-1415787
30 Jun 23102-1435887
31 Mar 23126-135600
31 Dec 22134-133610
30 Sep 22133-136630
30 Jun 2230136610
31 Mar 22227-29600
31 Dec 21207-36550
30 Sep 21198-33510
30 Jun 2121-212540
31 Mar 2118-202560
31 Dec 2021-190590
30 Sep 2022-169580
30 Jun 2019-148510
31 Mar 2023-127430
31 Dec 1921-105340
30 Sep 1924-92270
30 Jun 1928-76200
31 Mar 1928-62150
31 Dec 1828-52120
30 Sep 1822-45100
30 Jun 1815-3990
31 Mar 188-3580
31 Dec 174-3270
31 Dec 160-1520

Kwaliteitswinsten: ALEC is currently unprofitable.

Groeiende winstmarge: ALEC is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ALEC is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.

Versnelling van de groei: Unable to compare ALEC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ALEC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: ALEC has a negative Return on Equity (-106.71%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden